STOCK TITAN

T. Rowe Price holds 3.1% of Generation Bio (GBIO) shares

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed Amendment No. 8 to a Schedule 13G reporting its beneficial ownership of 209,641 shares of Generation Bio Co.3.1% of the class as of December 31, 2025.

T. Rowe Price reports sole voting and sole dispositive power over all 209,641 shares and no shared power. The firm states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Generation Bio.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



T. Rowe Price Associates, Inc.
Signature:Ellen York
Name/Title:Vice President
Date:02/17/2026

FAQ

What ownership stake in GBIO does T. Rowe Price report in this Schedule 13G/A?

T. Rowe Price Associates, Inc. reports beneficial ownership of 209,641 Generation Bio shares, representing 3.1% of the common stock as of December 31, 2025. This reflects a relatively small minority position in the company’s equity.

What type of SEC filing is this for Generation Bio (GBIO)?

This is an Amendment No. 8 to Schedule 13G for Generation Bio Co.. Schedule 13G is a beneficial ownership report used mainly by institutional investors holding shares without seeking to influence control of the issuer.

Does T. Rowe Price have voting and dispositive power over its GBIO shares?

Yes. T. Rowe Price reports sole voting power over 209,641 shares and sole dispositive power over the same amount. It reports no shared voting or shared dispositive power, indicating full control over how these specific shares are voted and sold.

Is T. Rowe Price’s Generation Bio (GBIO) stake above or below 5% ownership?

T. Rowe Price states its Generation Bio holding represents 3.1% of the class, which is 5 percent or less of the company’s common stock. The filing explicitly notes ownership of 5 percent or less of a class under Item 5.

What does T. Rowe Price say about its intentions regarding control of Generation Bio?

T. Rowe Price certifies the securities were acquired and are held in the ordinary course of business and not for changing or influencing control of Generation Bio. It also states they are not held in connection with any transaction having that control-related purpose or effect.

Who signed the Schedule 13G/A filing for T. Rowe Price on Generation Bio (GBIO)?

The filing is signed by Ellen York, identified as a Vice President of T. Rowe Price Associates, Inc. The signature block includes a certification that, after reasonable inquiry, the information in the statement is true, complete, and correct as of the stated date.
Generation Bio Co.

NASDAQ:GBIO

GBIO Rankings

GBIO Latest News

GBIO Latest SEC Filings

GBIO Stock Data

35.98M
5.78M
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE